Jun 30, 2021 / 02:00PM GMT
Operator
Good day, and thank you for standing by. Welcome to the ALN-AGT RNAi Roundtable. (Operator Instructions) Please be advised that today's conference may be recorded.
I'd now like to turn the conference over to Alnylam.
Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications
Good morning, everyone. Thank you for joining us today for this RNAi Roundtable, where we'll be discussing zilebesiran, or ALN-AGT, our investigational product in development for the treatment of hypertension. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. I'm joined today by Pushkal Garg, Chief Medical Officer at Alnylam, Dr. Elizabeth Ofili, Professor of Medicine at the Morehouse School of Medicine; Stephan Huang, Senior Director of Clinical Research at Alnylam; and Eric Green, Senior Vice President, Development programs at Alnylam.
In just a moment, I'll hand this over to Pushkal, but let me start with a few brief comments. Today's RNAi Roundtable is part of
Alnylam Pharmaceuticals Inc "RNAi Roundtable” Webcast Series: ALN-AGT, in Development for the Treatment of Hypertension Transcript
Jun 30, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers